IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
IceCure Medical (Nasdaq: ICCM) said the Society of Interventional Oncology submitted a petition to the NCCN Breast Cancer Guidelines Panel to add percutaneous cryoablation without surgical excision as a Category 2B option. The proposal targets patients 70+ meeting specific low-risk tumor criteria, and 50-69 poor surgical candidates or surgery decliners with cryoablation plus whole-breast radiation and endocrine therapy, citing FDA clearance of its ProSense system in Oct 2025.
How this was made
The 30-second read
Why it matters
The SIO petition requests NCCN Breast Cancer Guidelines Panel to add percutaneous cryoablation without surgical excision as Category 2B for carefully selected patients, potentially expanding the eligible population beyond the FDA-cleared 70+ cohort.
Market read
This is a concrete guideline-advocacy milestone tied to ProSense’s FDA authorization, which can influence clinician behavior and later reimbursement discussions if NCCN acts favorably.
What to watch
Adoption hinges on real-world clinician uptake, procedure capacity, and payer coverage; the article provides no data on utilization, pricing, or reimbursement changes following the FDA clearance.
Background
IceCure’s ProSense received FDA marketing authorization in October 2025 for local treatment of biologically low-risk breast cancer in women aged 70+ with tumors ≤1.5 cm on adjuvant endocrine therapy.
Ticker impact
IceCure says SIO petitioned NCCN Breast Cancer Guidelines to add percutaneous cryoablation as Category 2B, citing FDA clearance of its ProSense system.
Moderately positive bias for ICCM on the news, with follow-through dependent on whether NCCN accepts the petition and on any subsequent reimbursement or utilization updates.
The article discloses a concrete regulatory/guideline advocacy step tied to ProSense’s FDA marketing authorization, but it does not confirm NCCN acceptance, timing, or reimbursement outcomes.
Market effects
Could strengthen the read-through for minimally invasive oncology cryoablation and other non-surgical breast-conserving modalities if NCCN expands eligible populations.
Primarily US-focused via NCCN guideline process, with potential downstream effects on US clinical practice and reimbursement.
If NCCN expands indications, it may support broader global adoption narratives for ProSense, though the guideline is US-centric.
Counterpoint
NCCN guideline petitions often face delays or partial adoption, so the market may overprice the near-term impact before any formal NCCN decision or evidence update.
Key entities
- companyIceCure Medical Ltd.
Developer of liquid-nitrogen-based cryoablation systems, with ProSense FDA-cleared for biologically low-risk breast cancer in women aged 70+.
- organizationSociety of Interventional Oncology (SIO)
Submitted the formal petition to the NCCN Breast Cancer Guidelines Panel to consider cryoablation as a Category 2B option.
- organizationNational Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel
The panel that would decide whether to include the requested Category 2B footnote in its guidelines.
- productProSense cryoablation system
IceCure’s FDA marketing-authorized cryoablation device referenced as the basis for the petition’s recommendation.
